ProMIS Neurosciences to announce results in a presentation at the 2017 American Association of Neurology annual meeting
(Thomson Reuters ONE) -
TORONTO, Ontario - April 27, 2017 - ProMIS Neurosciences ("ProMIS" or the
"Company", TSE ticker PMN.TO), a company focused on the discovery and
development of precision treatments for neurodegenerative diseases, today
announced it will present results on its recent Alzheimer's disease (AD)
therapeutic developments on Friday, April 28(th) at the 2017 annual meeting of
the American Academy of Neurology (AAN), held in Boston, MA, from April 22-28.
"Based on our results presented at this year's AAN annual meeting we anticipate
ProMIS monoclonal antibodies (mAbs), selectively targeting toxic forms of
Amyloid beta (Aß), will demonstrate a 'best in class' product profile for
treatment of AD", stated Dr. Elliot Goldstein, ProMIS President and CEO.
"Indeed, by virtually no binding to Aß monomer, ProMIS mAb products should allow
improved efficacy by avoiding targeting of this abundant, non-toxic form of Aß.
Similarly, by not targeting plaque which is associated with neurovascular edema
('brain swelling'), a dose limiting adverse event, we anticipate improved safety
and tolerability for our products".
The presentation, entitled Achieving the optimal profile for Alzheimer's
immunotherapy: Rational generation of antibodies specific for toxic Aß oligomers
is a poster authored by Dr. Steven Plotkin (et al.), the Company's Chief Physics
Officer and presented by Dr. Johanne Kaplan, ProMIS Chief Development Officer.
Using one of the Company's unique, proprietary discovery platforms, Collective
Coordinates, the authors predicted five distinct epitopes (targets) on toxic
pathogenic Aß oligomers (prion-like forms of Aß). Results of the predictive
methodology indicate that these oligomer-specific epitopes are conformationally
distinct, in other words shaped differently from the same primary sequences in
either Aß monomer or fibrils, the latter representing the main constituent of
Aß plaque.
The authors conclude that monoclonal antibodies generated by immunizing with the
predicted conformational epitopes bind selectively to toxic Aß oligomers,
inhibit Aß propagation (spreading) in vitro, bind preferentially to AD brain
tissue and cerebrospinal fluid (CSF), show little or no reactivity to plaques in
cadaveric AD brain and protect against Aß toxicity in vitro. Furthermore, the
Company's lead product, PMN310, was shown to preserve cognitive function in a
preclinical animal model evaluating short term memory retention (dual object
recognition test).
About ProMIS Neurosciences, Inc.
The mission of ProMIS Neurosciences is to discover and develop precision
medicine therapeutics for effective treatment of neurodegenerative diseases, in
particular Alzheimer's disease and ALS.
ProMIS Neurosciences' proprietary target discovery engine is based on the use of
two, complementary techniques. The Company applies its thermodynamic,
computational discovery platforms-ProMIS((TM)) and Collective Coordinates - to
predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular
surface of misfolded proteins. Using this unique "precision medicine" approach,
ProMIS Neurosciences is developing novel antibody therapeutics and specific
companion diagnostics for Alzheimer's disease and ALS. The company has also
developed two proprietary technologies to specifically identify very low levels
of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences
owns a portfolio of therapeutic and diagnostic patents relating to misfolded
SOD1 in ALS, and currently has three preclinical monoclonal antibody
therapeutics against this target.
The information in this release may contain certain forward-looking information.
Such information involves known and unknown risks, uncertainties and other
factors that may cause actual results, performance or achievements to be
materially different from those implied by statements herein, and therefore
these statements should not be read as guarantees of future performance or
results. All forward-looking statements are based on the Company's current
beliefs as well as assumptions made by and information currently available to it
as well as other factors. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date of this press
release. Due to risks and uncertainties, including the risks and uncertainties
identified by the Company in its public securities filings, actual events may
differ materially from current expectations. The Company disclaims any intention
or obligation to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
For further information please consult the Company's website at:
www.promisneurosciences.com
Follow us on Twitter
Like us on LinkedIn
cbealamaro(at)streetwisereports.com
or contact
Dr. Elliot Goldstein
President and Chief Executive Officer, ProMIS Neurosciences Inc.
Tel. 415 341-5783
Elliot.goldstein(at)promisneurosciences.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ProMIS Neurosciences via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 27.04.2017 - 13:30 Uhr
Sprache: Deutsch
News-ID 538810
Anzahl Zeichen: 6082
contact information:
Town:
Toronto
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 161 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ProMIS Neurosciences to announce results in a presentation at the 2017 American Association of Neurology annual meeting"
steht unter der journalistisch-redaktionellen Verantwortung von
ProMIS Neurosciences (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
